A first-half slowdown in drug approvals was blamed for at least one earnings miss. But despite a softening financial outlook, it’s a far cry from the ‘pharmageddon’ days of 2008.
Perversely patient-centric? How data brokers figure out you’re pregnant
As the company largely pulls the plug on its commercial infrastructure for the prized Alzheimer’s asset, here’s what marketers can learn from the drug’s failure.
McKinsey, FDA and the case of the conflicted consultants